Cost of Chronic and Episodic Migraine. A pilot study from a tertiary headache centre in northern Italy

E Berra, G Sances, R De Icco, M Avenali, M Berlangieri, I De Paoli, M Bolla, M Allena, N Ghiotto, E Guaschino, S Cristina, C Tassorelli, G Sandrini, G Nappi, E Berra, G Sances, R De Icco, M Avenali, M Berlangieri, I De Paoli, M Bolla, M Allena, N Ghiotto, E Guaschino, S Cristina, C Tassorelli, G Sandrini, G Nappi

Abstract

Background: Chronic migraine (CM) has a high impact on functional performance and quality of life (QoL). CM also has a relevant burden on the National Health Service (NHS), however precise figures are lacking. In this pilot study we compared the impact in terms of costs of CM and episodic migraine (EM) on the individual and on the National Health System (NHS). Furthermore, we comparatively evaluated the impact of CM and EM on functional capability and on QoL of sufferers.

Methods: We enrolled 92 consecutive patients attending the Pavia headache centre: 51 subjects with CM and 41 with episodic migraine (EM). Patients were tested with disability scales (MIDAS, HIT-6, SF-36) and with an ad hoc semi-structured questionnaire.

Results: The direct mean annual cost (in euro) per patient suffering from CM was €2250.0 ± 1796.1, against €523.6 ± 825.8 per patient with EM. The cost loaded on NHS was €2110.4 ± 1756.9 for CM, €468.3 ± 801.8 for EM. The total economic load and the different sub-items were significantly different between groups (CM vs. EM p = 0.001 for each value). CM subjects had higher scores than EM for MIDAS (98.4 ± 72,3 vs 15.5 ± 17.7, p = 0.001) and for HIT-6 (66.1 ± 8.4 vs 58.7 ± 10.1, p = 0.001). The SF-36 score was 39.9 ± 14,74 for CM and 66.2 ± 18.2 for EM (p = 0.001).

Conclusions: CM is a disabling condition with a huge impact on the QoL of sufferers and a significant economic impact on the NHS. The adequate management of CM, reverting it back to EM, will provide a dual benefit: on the individual and on the society.

References

    1. Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210. doi: 10.1111/j.1468-2982.2007.01288.x.
    1. Berg J. Economic evidence inmigraine and other headaches: a review. Eur J Health Econ. 2004;5(1):43–54. doi: 10.1007/s10198-005-0288-z.
    1. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol. 2005;12(1):1–27. doi: 10.1111/j.1468-1331.2005.01202.x.
    1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition (beta version) Cephalalgia. 2013;33(9):629–808. doi: 10.1177/0333102413485658.
    1. Merikangas KR. Contributions of epidemiology to our understanding of migraine. Headache. 2013;53(2):230–246. doi: 10.1111/head.12038.
    1. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609.
    1. Mennini FS, Gitto L, Martelletti P. Improving care throught health economics analyses: cost of illness and headache. J Headache Pain. 2008;9:199–206. doi: 10.1007/s10194-008-0051-9.
    1. Fishman P, Von Korff M, Lozano P, Hecht J. Chronic care costs in managed care. Health Aff. 1997;16(3):239–247. doi: 10.1377/hlthaff.16.3.239.
    1. Berg J, Stovner LJ. Cost of migraine and other headaches in Europe. Eur J Neurol. 2005;12(1):59–62. doi: 10.1111/j.1468-1331.2005.01192.x.
    1. Andrée C, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, et al. The Eurolight project: the impact of primary headache disorders in Europe. Description of methods. J Headache Pain. 2011;12:541–549. doi: 10.1007/s10194-011-0356-y.
    1. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Ruiz De La Torre E, Tassorelli C, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19:703–e43. doi: 10.1111/j.1468-1331.2011.03612.x.
    1. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diarybased measure in a population sample of migraine sufferers. Pain. 2000;88:41–52. doi: 10.1016/S0304-3959(00)00305-5.
    1. Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine. Cephalalgia. 2011;31(3):357–367. doi: 10.1177/0333102410379890.
    1. Wang SJ, Fuh JL, Lu SR, Juang KD. Quality of life differs among headache diagnoses: analysis of SF-36 survey in 901 headache patients. Pain. 2001;89(2–3):285–292. doi: 10.1016/S0304-3959(00)00380-8.
    1. Normativa Ministero della Salute. . Accessed December 2013.
    1. DRG.. Accessed December 2013.
    1. Federfarma, . Accessed December 2013
    1. Openepi, . Accessed February 2014
    1. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MFT, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2009;49:498–508. doi: 10.1111/j.1526-4610.2009.01369.x.
    1. Stokes M, Becker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS) Headache. 2011;51:1058–1077. doi: 10.1111/j.1526-4610.2011.01945.x.
    1. Bloudek LM, Stokes M, Buse DC, Wilcox TC, Lipton RB, Goadsby PJ, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS) J Headache Pain. 2012;13:361–378. doi: 10.1007/s10194-012-0460-7.
    1. The Eurostat database. Eurostat. Yearbook 2010. Accessed Jan 10, 2011.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren